BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 19363798)

  • 1. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease.
    Gisbert JP; McNicholl AG; Gomollon F
    Inflamm Bowel Dis; 2009 Nov; 15(11):1746-54. PubMed ID: 19363798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal lactoferrin, a marker of intestinal inflammation in children with inflammatory bowel disease.
    Borkowska A; Liberek A; Łuczak G; Jankowska A; Plata-Nazar K; Korzon M; Kamińska B
    Acta Biochim Pol; 2015; 62(3):541-5. PubMed ID: 26339799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of four fecal assays in the diagnosis of colitis.
    Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
    Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal markers: calprotectin and lactoferrin.
    Abraham BP; Kane S
    Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calprotectin or Lactoferrin: Do They Help.
    Wright EK
    Dig Dis; 2016; 34(1-2):98-104. PubMed ID: 26982329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
    Stragier E; Van Assche G
    Acta Gastroenterol Belg; 2013 Sep; 76(3):322-8. PubMed ID: 24261027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?
    Di Ruscio M; Vernia F; Ciccone A; Frieri G; Latella G
    Inflamm Bowel Dis; 2017 Dec; 24(1):78-92. PubMed ID: 29272479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.
    Sipponen T
    Dig Dis; 2013; 31(3-4):336-44. PubMed ID: 24246984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of faecal inflammatory marker concentration as a noninvasive method of evaluation of pathological activity in children with inflammatory bowel diseases.
    Roszak D; Gałęcka M; Cichy W; Szachta P
    Adv Med Sci; 2015 Sep; 60(2):246-52. PubMed ID: 25989184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between fecal lactoferrin and inflammatory bowel disease.
    Dai J; Liu WZ; Zhao YP; Hu YB; Ge ZZ
    Scand J Gastroenterol; 2007 Dec; 42(12):1440-4. PubMed ID: 17852860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
    Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
    Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases.
    Langhorst J; Boone J
    Drugs Today (Barc); 2012 Feb; 48(2):149-61. PubMed ID: 22384454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
    Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
    Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.
    Kane SV; Sandborn WJ; Rufo PA; Zholudev A; Boone J; Lyerly D; Camilleri M; Hanauer SB
    Am J Gastroenterol; 2003 Jun; 98(6):1309-14. PubMed ID: 12818275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.
    Gisbert JP; McNicholl AG
    Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.
    Wang Y; Pei F; Wang X; Sun Z; Hu C; Dou H
    Int J Clin Exp Pathol; 2015; 8(10):12319-32. PubMed ID: 26722419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of fecal biomarkers in inflammatory bowel disease.
    Sutherland AD; Gearry RB; Frizelle FA
    Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.